-
公开(公告)号：EP1657250A1
公开(公告)日：2006-05-17
申请号：EP04026827.8
申请日：2004-11-11
IPC分类号： C07K14/47 , A61K39/00 , C07K7/04 , G01N33/574 , C12Q1/68
CPC分类号： C07K14/4748 , C12Q1/6886 , C12Q2600/158 , G01N33/57426
摘要： The present invention refers to an immunogenic HLA-A*01-binding T-cell epitope of the Wilms' tumour 1 protein (WT1) and its utility as a target in immunotherapy. In more detail, the invention refers to a polypeptide comprising an amino acid sequence as depicted in SEQ ID NO: 1, to an antibody directed to said polypeptide, to a polynucleotide encoding said amino acid sequence and to a polynucleotide which is complementary to said polynucleotide. The invention further refers to pharmaceutical compositions and in vitro applications.
摘要翻译： 本发明涉及Wilms肿瘤1蛋白（WT1）的免疫原性HLA-A * 01结合T细胞表位及其在免疫治疗中的用途。 更详细地，本发明涉及包含SEQ ID NO：1所示氨基酸序列，针对所述多肽的抗体，编码所述氨基酸序列的多核苷酸和与所述多核苷酸互补的多核苷酸的多肽 。 本发明还涉及药物组合物和体外应用。
-
公开(公告)号：EP4233851A1
公开(公告)日：2023-08-30
申请号：EP22158721.5
申请日：2022-02-25
IPC分类号： A61K31/00 , A61K31/506 , A61K31/5377 , A61P9/00 , A61P21/00 , A61P25/28 , A61P43/00
摘要： The invention relates to a pharmaceutical composition comprising a soluble guanylate cyclase stimulator or salt thereof for use in the treatment of a medical condition comprising a chronic vascular dysfunction occurring or persisting after onset of an infection in a human subject. In preferred embodiments, the invention relates to a pharmaceutical composition comprising a soluble guanylate cyclase stimulator or salt thereof, preferably vericiguat, for use in the treatment of a chronic vascular dysfunction associated with vascular constriction, endothelial dysfunction and/or hypo-perfusion.
-
搜索结果
2 条记录 (耗时 0.008 秒)
